MZT2B promotes malignant phenotypes in NSCLC cells by enhancing mitochondrial function and COX5B expression
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-11 03:44
摘要：
MZT2B is identified as a novel oncogenic driver in non-small cell lung cancer (NSCLC), correlating with adverse clinicopathological features and poor prognosis. The study demonstrates that MZT2B enhances mitochondrial function and promotes aggressive phenotypes in NSCLC cells, partially through the regulation of COX5B expression. These findings suggest that targeting MZT2B may provide a new therapeutic strategy for NSCLC, highlighting its potential as a diagnostic and prognostic biomarker.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
MZT2B is significantly upregulated in NSCLC tissues, correlating with poor prognosis.
MZT2B regulates mitochondrial function and promotes NSCLC progression via COX5B.
MZT2B knockdown impairs NSCLC tumor growth in vivo.
真实性检查
否
AI评分总结
MZT2B is identified as a novel oncogenic driver in non-small cell lung cancer (NSCLC), correlating with adverse clinicopathological features and poor prognosis. The study demonstrates that MZT2B enhances mitochondrial function and promotes aggressive phenotypes in NSCLC cells, partially through the regulation of COX5B expression. These findings suggest that targeting MZT2B may provide a new therapeutic strategy for NSCLC, highlighting its potential as a diagnostic and prognostic biomarker.